BVXV - ビオンドバックス・ファ―マス―ティカルズ （BiondVax Pharmaceuticals Ltd.）

BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company developing unique NanoAb immunotherapeutic products for the treatment of infectious disease and large market autoimmune disorders, recently published the financial results for the three months ended March 31, 2023 – Q1 2023 – and provided a business update (https://nnw.fm/qkIoO). The Q1 2023 results were in line with … Continue reading "BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update" The post BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives Buy Rating and $70 Target Price; Releases Q1 2023 and Business Update appeared first on NetworkNewsWire .

Biondvax Pharmaceuticals press release (BVXV): Q1 GAAP EPS of $0.00 beats by $0.73.As of March 31, 2023, BiondVax had cash and cash equivalents of $10.9 million as compared to…

JERUSALEM, ISRAEL / ACCESSWIRE / May 15, 2023 / (via IBN) -- BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovativ…

JERUSALEM, ISRAEL / ACCESSWIRE / May 15, 2023 / (via IBN) -- BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its financial results for the first quarter ended March 31, 2023, and provided a business update. First Quarter 2023 Financial Summary R&D expenses for the three months ended March 31, 2023, amounted to $2 million compared with $1.2 million for the three months ended March 31, 2022. The increase of $0.8 million was primarily due to the initiation of R&D activities for the innovative nanosized antibody (NanoAb) platform. Marketing, general and administrative expenses for the three months ended March 31, 2023, amounted to $1.2 million compared with $1.4 million for the three months ended March 31, 2022. Total operating expenses for the three months ended March 31, 2023, amounted to $3.2 million compared with $2.6 for the three months ended March 31, 2022.

The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars – the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of keynotes from life science executives, fireside chats, panel discussions, and presentations that allowed … Continue reading "BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland" The post BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland appeared first on BioMedWire (BMW) .

BiondVax Pharmaceuticals Ltd. saw a significant drop in short interest in May. As of May 15th, there was short interest totalling 61,600 shares, a drop of 16.4% from the April…

Biondvax Pharmaceuticals press release (BVXV): Q1 GAAP EPS of -NIS0.02.Cash and cash equivalents NIS48.89M.

JERUSALEM, June 1, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its…

JERUSALEM, May 19, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that…

Clever Leaves Holdings CLVR -20% after sharp rally last week.Companhia Energetica (CIG) -15%.BiondVax Pharmaceuticals BVXV -9% on FY earnings release.Enservco (ENSV) -8% announces…

Clever Leaves Holdings CLVR -20% after sharp rally last week.Companhia Energetica (CIG) -15%.BiondVax Pharmaceuticals BVXV -9% on FY earnings release.Enservco (ENSV) -8% announces…

Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV ) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies. BiondVax says the company is planning a rapid development path that leverages the company''s expertise and capabilities in biological drug development and manufacturing. BiondVax notes that … Full story available on Benzinga.com

BiondVax Pharmaceuticals BVXV +39%. Alpha Tau Medical (DRTS) +38%. Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%.

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has a beta value of 2.26 and has seen 100.08 million shares traded in the recent trading session. The company, currently valued at $21.47M, closed the recent trade at $2.88 per share which meant it gained $1.4 on the day or 94.93% during that session. The BVXV stock price is -150.69% 94.93% Gain Drives BiondVax Pharmaceuticals Ltd. (BVXV) Into Becoming A Interest-Loosing Stock For Investors Read More »

Biondvax Pharmaceuticals (BVXV) stock is on the rise Wednesday thanks to some positive news concerning its Covid-19 antibodies.